Tofacitinib an alternative treatment for refractory cutaneous dermatomyositis

Tofacitinib, an oral Janus kinase (JAK)-1/3 inhibitor approved for treating rheumatoid arthritis, was beneficial in treating cutaneous dermatomyositis in three patients who had failed traditional therapies, according to a report published in JAMA Dermatology. Dr. Drew J.B. Kurtzman of the...
Source: Skin and Allergy News - Category: Dermatology Source Type: news